LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Rapid Lateral Flow Antigen COVID-19 Testing Platform Processes 200-300 People Each Hour and Reports Results in 15 Minutes

By LabMedica International staff writers
Posted on 20 Oct 2020
Print article
Illustration
Illustration
A new rapid lateral flow antigen COVID-19 testing platform gives testers the ability to process an unprecedented 200-300 people each hour and report results within 15 minutes utilizing testing kits from Quidel, BD and Abbott.

The COVID CleanPass system from Apollo Medco (Atlanta, GA, USA) is a mobile app-linked, HIPAA compliant, cloud secure and data-backed COVID-19 testing platform. Straight forward and effortless to operate, its built-in software walks anyone through all and every step of testing. Its trouble-free transportability and total weight of less than 20 pounds makes any location perfect for use. Its bulletproof and waterproof case floats and protects all electronics inside, no matter how harsh the environment. In case of power failure, its eight-hour battery or solar powered panels ensure that testing continues.

Hassle-free, simple to operate, and compatible with worldwide power sources, the COVID CleanPass is a reliable system that is enabling businesses across the globe to reopen and start growing with absolute peace of mind. With its compact form and overhead airline compliance, immediate global deployment to the next viral outbreak is actually possible. Currently, Apollo Medco is beta testing its COVID-19 testing platform and applying for Emergency Use Authorization from the US Food and Drug Administration which is expected in November 2020. Distribution of the new COVID CleanPass system is then expected to begin in late November 2020.

"Our new COVID CleanPass platform is the most advanced, quality-assured, rapid testing platform in the world," said Apollo Medco President & CEO Ken Dunwody. "We've supercharged the overall COVID testing process by delivering fast and accurate results to the patient in an efficient manner. The front-end of our platform includes our Apollo 'Mission Control' diagnostic unit while the back-end of our platform includes our mobile app-linked, cloud secure, HIPAA compliant test reporting system which includes a dynamic Web portal that maps, tracks and reports COVID hot zones in real time."

"Each Apollo Medco testing system is contained in a portable rugged case and includes a battery that lasts 10 hours, iPad with the proprietary mobile app system, time tracking system, printer and a universal lateral flow analysis device. All testing companies will have access to our HIPPA compliant Web portal for accepting new testing requests, scheduling, assigning systems to testers and managing testing assignments. Automatic reporting of all COVID-19 tests through the Apollo Medco COVID CleanPass system will enable testing companies to provide quick, accurate information," added Dunwody.

Related Links:
Apollo Medco

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more